(OMDA) Omada Health BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(OMDA) Omada Health Complete Analysis Pack
Visual. Strategic. Downloadable.
This Omada Health BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The page already includes a real preview of the analysis, so you can review the format and content before buying, while the full purchase unlocks the complete ready-to-use version.
Stars
Cardiometabolic platform
Omada Health’s cardiometabolic platform is its clearest Star: it bundles diabetes, hypertension, weight, and risk care into one recurring-contract model in a huge chronic-care market. The U.S. alone has 38.4 million people with diabetes and about 120 million adults with hypertension, so demand stays deep and sticky. That mix of scale, repeat use, and cross-condition management makes it the company’s most defensible growth engine.
Type 2 diabetes management
Omada Health’s Type 2 diabetes management fits a Star: diabetes affects 38.4 million Americans, with 97.6 million more living with prediabetes, so the addressable market is huge. This is one of Omada Health’s most proven lines, and employers and health plans keep renewing for virtual support, which supports strong adoption and repeat revenue.
Hypertension program
Omada Health’s hypertension program fits Star territory because blood-pressure care is a high-need, high-volume virtual use case, and Omada can layer monitoring, coaching, and escalation across a broad covered population. The category has strong demand from employers and health plans, and BP control is a measurable outcome that supports repeat use and contract retention. Growth still looks strong, so this remains a priority engine.
GLP-1 support
GLP-1 support is a Star for Omada Health because obesity care is scaling fast in 2025, and the U.S. adult obesity rate is about 42%. Omada’s coaching fits adherence, side-effect checks, and lifestyle follow-through, which matter when GLP-1s drive persistent use and drop-off risk. The segment is still expanding, so it needs continued investment to defend growth.
- 42% U.S. adult obesity rate
- Coaching supports medication adherence
- Growth still needs more capital
Connected devices and coaching
Omada Health’s connected tools and coaching fit Star behavior: they drive engagement in a fast-growing category. Its scale, blood-pressure cuffs, and human coaches help members manage diabetes, hypertension, and musculoskeletal care in one model. The company says it serves 2,000+ customers and reaches 29 million+ covered lives, which supports retention and share gains.
- Scale lifts member reach
- Cuffs make tracking easier
- Coaches keep users engaged
- Multi-condition care boosts retention
Omada’s Cardiometabolic Stars Fuel Growth
Omada Health’s Stars are its cardiometabolic lines: diabetes, hypertension, obesity, and GLP-1 support. With 38.4 million Americans with diabetes, about 120 million with hypertension, and roughly 42% U.S. adult obesity, these programs sit in large, recurring-care markets that drive retention and contract renewals.
| Star | Why it wins |
|---|---|
| Cardiometabolic | Huge, repeat demand |
| Diabetes | 38.4M U.S. cases |
| Hypertension | 120M adults affected |
| GLP-1 support | 42% obesity rate |
What is included in the product
Detailed Word Document
Omada Health BCG Matrix shows which digital health offerings to invest in, hold, or divest across Stars, Cash Cows, Questions, and Dogs.
Editable Excel File
Clear BCG view of Omada Health’s business units to quickly spot pain points and priorities.
Reference Sources
Provides a clear source trail to validate assumptions, boost credibility, and speed investor or internal decision-making.
Cash Cows
Prediabetes program
Omada Health’s Prediabetes program is the company’s mature preventive-care base: it has been in market for years, has established buyer awareness, and supports recurring enrollment. In 2024, Omada Health reported $169.8 million of revenue, underscoring the scale of this cash-generating core. That steady demand profile fits a Cash Cow in the BCG matrix.
Enterprise renewals
Omada Health’s enterprise renewals fit Cash Cow economics because the Company sells mainly to employers and health plans on subscription-style contracts, so recurring revenue matters more than new-logo wins. A large installed base usually renews at lower sales cost than net-new accounts, which supports steadier cash flow and margin. That makes retention a more valuable driver than rapid expansion.
PMPM recurring revenue
Omada Health’s PMPM recurring revenue is a classic cash cow: once a client signs, monthly per-member billing can keep cash coming in with lower servicing costs than winning new accounts. The model is built for predictability, especially in a mature, high-share category. That said, I can’t verify 2025/2026 disclosure numbers here without live filings.
Existing member cohorts
Existing member cohorts are cheaper to serve than new members, since Omada Health can monetize renewals and ongoing care without repeating heavy launch spend. That makes the base attractive in 2025: low growth, high retention, and recurring revenue from long-tenured users fit the Cash Cow profile. The more members stay, the more Omada Health can harvest margin from a stable installed base.
- Lower servicing cost
- Recurring revenue stream
- High retention base
- Minimal launch spend
Core virtual coaching
Core virtual coaching is a cash cow because digital coaching is now a standard buy in chronic-care deals, and Omada Health can spread its playbook across 700,000+ members without matching product spend one for one. That means more service volume can lift margin before it lifts growth. The setup favors cash generation, not heavy reinvestment.
- Standard feature in chronic-care purchasing
- Operational reuse lowers marginal cost
- Cash generation beats rapid growth
Omada’s cash cows: renewals fueling growth
Omada Health’s Cash Cows are its mature enterprise renewals and PMPM contracts, where retention drives cash more than new sales. In 2024, revenue reached $169.8 million, and the installed member base is cheaper to serve than new launches.
| Metric | Value |
|---|---|
| 2024 revenue | $169.8M |
| Cash cow driver | Renewals |
What You See Is What You Get
Omada Health Reference Sources
The Omada Health BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the full, ready-to-use file. It’s formatted for clear strategic analysis and professional presentation. Once purchased, your download will match this preview exactly.
Dogs
Legacy education-only content
Omada Health's legacy education-only content fits a Dog in BCG terms: it is easy to copy, has weak pricing power, and usually grows slower than device-, data-, or coaching-led programs. Omada's moat is stronger in behavior change tied to outcomes, not in standalone content. Without a clear 2025-2026 monetization edge, this slice is likely low-return capital.
One-off pilot programs
One-off pilot programs fit Dogs in Omada Health’s BCG Matrix because they usually have low share, weak repeat use, and uncertain conversion into long-term contracts. They also soak up sales and implementation time without reliable recurring revenue, so the payoff stays thin. If pilot-heavy work keeps growth below the core business, it remains a low-return use of capital.
Commodity digital navigation
Commodity digital navigation is table stakes across health tech, so Omada Health does not earn premium pricing unless it ties navigation to measurable clinical outcomes. In BCG terms, this sits in low-growth, low-share territory: easy to copy, hard to defend, and usually thin-margin. Without a 2025-2026 proof point that lifts retention or lowers care costs, the feature stays a Dogs asset.
Small niche employer deals
Small niche employer deals fit Dogs because very small accounts rarely add scale. They can raise onboarding, support, and reporting work without meaningfully lifting revenue, so the payoff stays thin. In BCG terms, that usually means low share in a low-growth pocket.
- Small lives, low revenue lift
- Higher service cost per account
- Limited scaling value for Omada Health
Non-core manual services
Non-core manual services fit the Dogs quadrant because they need staff-heavy delivery, so costs rise faster than growth. If they are not linked to Omada Health's core clinical engine, they can pull margin down instead of adding scale. In digital health, manual work is a drag, not a moat.
- High labor cost
- Poor scaling economics
- Weak fit with core care
- Capital drain risk
Omada’s Dog Businesses Drain Margin
Dogs in Omada Health’s BCG mix are low-share, low-growth lines like legacy education, one-off pilots, small employer deals, and manual services. They bring weak pricing power, high support load, and little repeat revenue. These pieces can drain margin unless they tie to measurable outcomes or recurring contracts.
| Dog area | Why it fits |
|---|---|
| Pilots | Low repeat use |
| Small deals | High service cost |
| Manual work | Poor scale |
Question Marks
Musculoskeletal care
Digital musculoskeletal care is growing fast, but it is still crowded and split across many point solutions. Musculoskeletal disorders affect about 1.7 billion people worldwide and are a top cost driver, with U.S. claims often tied to roughly $420 billion a year in spending. Omada Health has not built the same scale or brand strength here as in cardiometabolic care, so this fits a Question Mark.
Behavioral health expansion
Behavioral health demand keeps rising, with 1 in 8 people worldwide living with a mental disorder, but the market is crowded and buyer budgets are tight. Omada Health still must show strong engagement and measurable outcomes before employers will pay more. With share still unclear and economics unproven, behavioral health expansion fits a Question Mark in the BCG Matrix.
CKD risk management
CKD risk management sits next to cardiometabolic care, so payers can buy it through the same cost-avoidance logic: CKD affects about 1 in 7 U.S. adults, and Medicare spends well over $130 billion a year on kidney disease care. Omada Health has a clear market, but it is not yet the dominant kidney player, so this is still a Question Mark. The upside is real, but share must grow fast to justify the investment.
Women’s metabolic health
Women’s metabolic health sits in the Question Mark box for Omada Health: demand is rising in 2025, but leadership is still fragmented. In the U.S., heart disease causes 1 in 5 female deaths, and PCOS affects about 6% to 12% of women of reproductive age, so the addressable need is real. To turn this into a Star, Omada would need heavier product, clinical, and go-to-market investment.
- Fast-growing 2025 demand
- Leadership still unsettled
- High-need, high-need market
- Needs investment to scale
Provider-integrated partnerships
Provider-integrated partnerships are a Question Mark for Omada Health because health-system and value-based care ties can open new referral flow and deeper clinical data, but scale is still early. In 2025, the company was still building this channel while serving more than 1 million members, so the upside is real, but current share is still limited.
- High upside, low share.
- Better referrals, richer data.
- Adoption still early in 2025.
Omada’s Next Bets: Big Markets, Early Proof Needed
Omada Health’s Question Marks are the newer adjacencies with real demand but weak share. Musculoskeletal care, behavioral health, and CKD all sit in large, costly markets, yet Omada is still early and must prove scale, engagement, and payback in 2025-2026.
| Area | 2025/2026 signal |
|---|---|
| MSK | 1.7 billion cases globally; $420 billion U.S. cost |
| Behavioral health | 1 in 8 people affected worldwide |
| CKD | 1 in 7 U.S. adults; Medicare spend > $130 billion |
That makes the upside clear, but each line still needs investment before it can move from Question Mark to Star.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.